Print this page    •   Back to Web version of article

Strategy Update: Protease-Sparing Regimens

December 1998

Since the Geneva International AIDS Conference, the notion of using therapy combinations which delay the use of protease inhibitors has been a hotly debated topic. The rationale for protease-sparing regimens is to use a three-drug combination that reduces viral load below the limit of detection while saving protease inhibitors for later use. The theoretical advantage of a protease-sparing regimen is not only that it saves the most potent therapy for later use, but that it also delays the risk of side effects associated with long-term use of protease inhibitors. Those who promote the protease-sparing regimens believe that this makes for a better long-term strategy and may extend the length of time that drugs are effective.

Not everyone agrees with the rationale behind protease-sparing regimens. Some researchers still believe that the best shot a person has against HIV infection is the first shot. They argue that even initial therapy should begin with our strongest anti-HIV drugs. This, they believe, will result in the longest duration of effective therapy while also introducing the most potent drugs at a time when the patient is in the best health and best able to fend off side effects. At the moment, there simply is no hard data to say which of these strategies will help a person live longer. They are simply matters of opinion.

In recent months, the promotion of protease-sparing regimens, particularly with the use of efavirenz (Sustiva®), has reached a fever pitch. Many doctors are routinely using the efavirenz regimen as a first choice for people just starting therapy, and some cases, taking people off of protease inhibitor combinations in favor of an efavirenz combination. The data which serves as the primary justification for using the efavirenz / protease-sparing regimen is a single trial in people who have never previously taken anti-HIV therapy which compared the efavirenz combination to a typical indinavir (Crixivan®) combination. That study, reported in PI Perspective 25, seemed to show the efavirenz combination to be equal, if not superior, to the indinavir combination. Even though the simplicity of use offered by efavirenz is a real benefit, there is good reason for caution in making wholesale judgments about the value of this approach. They can be easily summarized:

Promoters of the efavirenz combination also strongly imply that efavirenz is a better choice for such protease-sparing regimens than other drugs in this class, notably nevirapine and delavirdine. Salesmanship aside, there is simply no evidence to support this view. No studies have directly compared efavirenz to other drugs in its class. Both nevirapine and delavirdine came to market with the reputation of being somewhat weaker than protease inhibitors, but this perception was derived primarily from studies which used them in inadequate, two-drug combinations. Subsequent 3-drug combinations using either drug as the anchor for a regimen have shown results similar to the efavirenz study in regards to the percentage of people who achieve viral load below the level of detection. Since efavirenz has been priced nearly 60% to 70% above nevirapine and delavirdine respectively, the comparative value of these three drugs is important. Until directly comparative studies are run, there is no valid basis for suggesting that any one of them is superior to any other. In other words, people contemplating the use of a protease-sparing regimen should not automatically assume that such a regimen must be based on the use of efavirenz. Whether efavirenz, delavirdine or nevirapine is used as an anchor for a protease-sparing regimen, it is important to use any of these drugs in combination with at least two nucleoside analogue drugs (e.g. AZT [zidovudine, Retrovir®], ddI [Videx®], d4T [Zerit®], etc.) which are new to the individual.

While the three drugs are probably roughly equivalent, no head-to-head comparative studies have yet been conducted. Some issues to consider when making a decision about the three drugs might include their dosing schedules, side effect profiles and drug interactions. Efavirenz is probably the easiest drug to use, requiring only once daily dosing. Of the three drugs, it probably has the most side effects, however. Like the protease inhibitors, efavirenz has been shown to elevate triglycerides and cholesterol levels, in some people. People considering a protease-inhibitor-sparing regimen because of fears the long-term effects of elevated cholesterol and triglyceride levels should be aware that this is also a potential side effect of this drug. Moreover, efavirenz use is associated with neurologic side effects, including bizarre dreams, feelings of disorientation and feelings of being "hungover." Delavirdine is commonly being used as an adjunctive therapy to a protease inhibitor containing regimen, to modulate the blood levels of other drugs to allow for decreasing dosing. In general practice today, delavirdine is rarely the cornerstone of a triple-drug regimen. This was because early studies were not conducted using delavirdine in a 3-drug regimen (only in 2-drug regimens) and its effective was under question. More recent study results, where delavirdine was used in a 3-drug combination, showed that it was potent when used in an optimal strategy regimen with two other drugs. While it requires three times daily dosing, it is probably causes the least side effects of the three drugs. While both delavirdine and nevirapine has rash as the most common side effect, the incidence of rash is much lower among people using delavirdine. Nevirapine requires only twice daily dosing, making it easier to take than delavirdine and because it doesn't have the additional neurologic and metabolic (e.g. increasing cholesterol/triglycerides) side effects of efavirenz it is increasingly being used as the "middle ground" option for people choosing a protease-inhibitor-sparing regimen, particularly for people who are co-infected with HIV and hepatitis or who have other signs or symptoms of impaired liver function.

While not a concern in protease sparing regimens, an additional point to consider arises when efavirenz is used in combination with a protease inhibitor. When used in combination, the drug substantially diminishes the level of some protease inhibitors. Indinavir levels are reduced by 31% and saquinavir (Fortovase®) levels are reduced by 62%. As a result, when efavirenz is combined with either of these protease inhibitors, the dose of the protease inhibitor needs to be adjusted. Nevirapine (Viramune®) will also, to a lesser degree, reduce indinavir and saquinavir levels, while delavirdine (Rescriptor®) has the opposite effect, increasing the blood levels of some protease inhibitors. This property of delavirdine may allow for either reduced doses of protease inhibitors or increased potency.


None of these concerns rule out the use of efavirenz or protease-sparing regimens in general. The unresolved question of long-term durability applies equally to all drugs in the non-nucleoside class and lead some researchers to believe that the best use of this class of drugs will be in combination with protease inhibitors, rather than as an alternative. It is critical to remember that if a patient develops resistance to any of the three current non-nucleoside drugs in a protease-sparing regimen, this class of drugs will not be useful later in the course of HIV disease.

The bottom line is that no one has adequate information to make proven recommendations about the use of these protease-sparing regimens, or about the comparative value of efavirenz, nevirapine and delavirdine. For some people, the simpler dosing regimens offered by all the non-nucleosides may be a compelling, overriding factor in choosing a combination. For others, concerns about the long-term outcome may outweigh factors of convenience. Given a few more years and a few directly comparative trials, people may not have to choose in this manner, but for now, it is all that the data will allow.

Expanded Access

These new drugs are currently available free of charge while awaiting final FDA approval.

Amprenavir (PI)   800-248-9757
For anyone tolerate or failing current protease inhibitor therapy and requiring an additional new drug for treatment strategy.

Abacavir (NARTI)   800-501-4672
For anyone failing current therapy and requiring an additional new drug for treatment strategy.

Adefovir (NtARTI)   800-445-3235
For anyone failing current therapy and requiring an additional new drug for treatment strategy.

Back to the Project Inform Perspective December 1998 contents page.

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.